Lobbying Governance
| Overall Assessment | Analysis | Score |
|---|---|---|
| Limited |
Towa Pharmaceutical discloses a basic approach to keeping its trade-association work broadly consistent with its climate goals, stating that it is a member of “日本ジェネリック製薬協会（JGA）” and that “当社からの参加メンバーはJGAの環境委員会委員長を務め、日薬連の環境委員会と協働でカーボンニュートラルへの取組や廃棄物の削減等のデータの収集、情報提供等の推進に努めています.” This indicates the company is actively using its position within the association to promote carbon-neutral initiatives, suggesting some effort to align indirect lobbying with its own climate commitment to “2030年時点のグループ全体のScope1,2の排出量を30％削減” under the Japan Business Federation’s “カーボンニュートラル行動計画.” However, the disclosure does not describe any formal governance mechanism—there is no explanation of how lobbying positions are reviewed, no description of monitoring procedures, and no identification of a board committee or senior executive responsible for overseeing lobbying alignment. As such, while the company acknowledges climate-related engagement through an industry body, it provides only limited evidence of a structured lobbying-governance framework.
View Sources
|
D |